Larimar Therapeutics Inc. Company Profile
NASDAQ: LRMRHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Larimar Therapeutics at a glance
Larimar Therapeutics Inc. (NASDAQ: LRMR) is a Biotechnology company in the Healthcare sector headquartered in Bala Cynwyd, PA. Larimar Therapeutics is led by Dr. Carole S. Ben-Maimon M.D. and employs about 71 people. The company's shares have traded publicly since 2014.
At a market capitalization of $288.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001374690, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Larimar Therapeutics do?
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Larimar Therapeutics Inc.
- Ticker
- NASDAQ: LRMR
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Carole S. Ben-Maimon M.D.
- Employees
- 71
- Headquarters
- Three Bala Plaza East, Bala Cynwyd, PA, United States
- Phone
- 844 511 9056
- Website
- larimartx.com
- IPO year
- 2014
- Market cap
- $288.79M
- SEC CIK
- 0001374690
Companies similar to Larimar Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABEOAbeona Therapeutics Inc. | 5.08 | +1.40% | $290.49M | vs LRMR |
| CUVLClinuvel Pharmaceuticals Limited ADR | 5.80 | +2.29% | $292.83M | vs LRMR |
| SRZNSurrozen Inc. | 25.15 | -4.65% | $295.54M | vs LRMR |
| FULCFulcrum Therapeutics Inc. | 3.67 | -0.54% | $280.01M | vs LRMR |
| XFORX4 Pharmaceuticals Inc. | 2.81 | +1.44% | $278.60M | vs LRMR |
| EYPTEyePoint Inc. | 3.32 | +4.73% | $278.35M | vs LRMR |
| RCKTRocket Pharmaceuticals Inc. | 2.54 | +2.22% | $278.28M | vs LRMR |
| INDPIndaptus Therapeutics Inc. | 2.26 | -12.74% | $301.13M | vs LRMR |